254 related articles for article (PubMed ID: 19772793)
1. Association of rheumatoid arthritis with Mdm2 SNP309 and genetic evidence for an allele-specific interaction between MDM2 and p53 P72R variants: a case control study.
Assmann G; Voswinkel J; Mueller M; Bittenbring J; Koenig J; Menzel A; Pfreundschuh M; Roemer K; Melchers I
Clin Exp Rheumatol; 2009; 27(4):615-9. PubMed ID: 19772793
[TBL] [Abstract][Full Text] [Related]
2. Polymorphisms in the TP53-MDM2-MDM4-axis in patients with rheumatoid arthritis.
Gansmo LB; Lie BA; Mæhlen MT; Vatten L; Romundstad P; Hveem K; Lønning PE; Knappskog S
Gene; 2021 Aug; 793():145747. PubMed ID: 34077778
[TBL] [Abstract][Full Text] [Related]
3. Interaction between p53 codon 72 and MDM2 309T>G polymorphisms and the risk of hepatocellular carcinoma.
Qiu M; Liu Y; Yu X; Qin L; Bei C; Zeng X; Qiu X; Tang B; He S; Yu H
Tumour Biol; 2016 Mar; 37(3):3863-70. PubMed ID: 26476535
[TBL] [Abstract][Full Text] [Related]
4. MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma.
Hirata H; Hinoda Y; Kikuno N; Kawamoto K; Suehiro Y; Tanaka Y; Dahiya R
Clin Cancer Res; 2007 Jul; 13(14):4123-9. PubMed ID: 17634539
[TBL] [Abstract][Full Text] [Related]
5. Association of MDM2 and p53 polymorphisms with the advancement of cervical carcinoma.
Singhal P; Hussain S; Thakur N; Batra S; Salhan S; Bhambani S; Bharadwaj M
DNA Cell Biol; 2013 Jan; 32(1):19-27. PubMed ID: 23210739
[TBL] [Abstract][Full Text] [Related]
6. Single-nucleotide polymorphisms p53 G72C and Mdm2 T309G in patients with psoriasis, psoriatic arthritis, and SAPHO syndrome.
Assmann G; Wagner AD; Monika M; Pfoehler C; Pfreundschuh M; Tilgen W; Roemer K
Rheumatol Int; 2010 Aug; 30(10):1273-6. PubMed ID: 19779722
[TBL] [Abstract][Full Text] [Related]
7. A functional SNP in the MDM2 promoter, pigmentary phenotypes, and risk of skin cancer.
Nan H; Qureshi AA; Hunter DJ; Han J
Cancer Causes Control; 2009 Mar; 20(2):171-9. PubMed ID: 18814047
[TBL] [Abstract][Full Text] [Related]
8. [Association of murine double minute 2 and P53 polymorphisms with breast cancer susceptibility].
Wang ML; Xu YX; Qian J; Wang FH
Zhonghua Yu Fang Yi Xue Za Zhi; 2013 Feb; 47(2):124-8. PubMed ID: 23719102
[TBL] [Abstract][Full Text] [Related]
9. MDM2 promoter SNP309 is associated with an increased susceptibility to chronic lymphocytic leukemia and correlates with MDM2 mRNA expression in Chinese patients with CLL.
Dong HJ; Fang C; Fan L; Zhu DX; Wang DM; Zhu HY; Zhuang Y; Miao KR; Liu P; Xu W; Li JY
Int J Cancer; 2012 May; 130(9):2054-61. PubMed ID: 21647873
[TBL] [Abstract][Full Text] [Related]
10. Genotypic interaction and gender specificity of common genetic variants in the p53/mdm2 network in Crohn's disease.
Zimmer V; Widmann T; Müller M; Ong MF; Stein JM; Pfreundschuh M; Lammert F; Roemer K; Assmann G
Digestion; 2010; 81(4):246-51. PubMed ID: 20110711
[TBL] [Abstract][Full Text] [Related]
11. Association of breast cancer outcome with status of p53 and MDM2 SNP309.
Boersma BJ; Howe TM; Goodman JE; Yfantis HG; Lee DH; Chanock SJ; Ambs S
J Natl Cancer Inst; 2006 Jul; 98(13):911-9. PubMed ID: 16818855
[TBL] [Abstract][Full Text] [Related]
12. Risk of MDM2 SNP309 alone or in combination with the p53 codon 72 polymorphism in acute myeloid leukemia.
Xiong X; Wang M; Wang L; Liu J; Zhao X; Tian Z; Wang J
Leuk Res; 2009 Nov; 33(11):1454-8. PubMed ID: 19423162
[TBL] [Abstract][Full Text] [Related]
13. Association of MDM2 SNP309 and TP53 Arg72Pro polymorphisms with risk of endometrial cancer.
Yoneda T; Kuboyama A; Kato K; Ohgami T; Okamoto K; Saito T; Wake N
Oncol Rep; 2013 Jul; 30(1):25-34. PubMed ID: 23624782
[TBL] [Abstract][Full Text] [Related]
14. MDM2 SNP309, gene-gene interaction, and tumor susceptibility: an updated meta-analysis.
Wan Y; Wu W; Yin Z; Guan P; Zhou B
BMC Cancer; 2011 May; 11():208. PubMed ID: 21619694
[TBL] [Abstract][Full Text] [Related]
15. MDM2 promoter polymorphism is associated with increased susceptibility to hepatocellular carcinoma in Turkish population.
Akkiz H; Sümbül AT; Bayram S; Bekar A; Akgöllü E
Cancer Epidemiol; 2010 Aug; 34(4):448-52. PubMed ID: 20447891
[TBL] [Abstract][Full Text] [Related]
16. The p53 G72C and MDM2 T309G single nucleotide polymorphisms in patients with Wegener's granulomatosis.
Assmann G; Wieczorek S; Wibisono D; Roemer K; Arning L; Voswinkel J
Clin Exp Rheumatol; 2008; 26(3 Suppl 49):S72-5. PubMed ID: 18799058
[TBL] [Abstract][Full Text] [Related]
17. Effect of MDM2 SNP309 and p53 codon 72 polymorphisms on lung cancer risk and survival among non-smoking Chinese women in Singapore.
Chua HW; Ng D; Choo S; Lum SS; Li H; Soh LY; Sabapathy K; Seow A
BMC Cancer; 2010 Mar; 10():88. PubMed ID: 20219101
[TBL] [Abstract][Full Text] [Related]
18. Do CDKN2 p16 540 C>G, CDKN2 p16 580 C>T, and MDM2 SNP309 T>G gene variants act on colorectal cancer development or progression?
Tuna G; Küçükhüseyin O; Arıkan S; Kaytan Sağlam E; Güler E; Cacına C; Oztop O; Turan S; Korkmaz G; Yaylım I
DNA Cell Biol; 2013 Jul; 32(7):400-8. PubMed ID: 23777425
[TBL] [Abstract][Full Text] [Related]
19. Associations of MDM2 SNP309, transcriptional activity, mRNA expression, and survival in stage I non-small-cell lung cancer patients with wild-type p53 tumors.
Chien WP; Wong RH; Cheng YW; Chen CY; Lee H
Ann Surg Oncol; 2010 Apr; 17(4):1194-202. PubMed ID: 19941079
[TBL] [Abstract][Full Text] [Related]
20. Combined effects of single nucleotide polymorphisms TP53 R72P and MDM2 SNP309, and p53 expression on survival of breast cancer patients.
Schmidt MK; Tommiska J; Broeks A; van Leeuwen FE; Van't Veer LJ; Pharoah PD; Easton DF; Shah M; Humphreys M; Dörk T; Reincke SA; Fagerholm R; Blomqvist C; Nevanlinna H
Breast Cancer Res; 2009; 11(6):R89. PubMed ID: 20021639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
